跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BASAGLAR - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BASAGLAR
Authorized
STANDARD
BASAGLAR
eli lilly canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
4844682514caf3ba
Company
eli lilly canada inc
Type
Standard
Approval Details
Approval Id
4844682514caf3ba
Drug Approval Canada Name
BASAGLAR
Product Name
BASAGLAR
Status
Marketed
Status Date
2017-08-18
Original Market Date
2017-08-18
Din
02461528
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D
Ahfs
68:20.08
Atc Original
A10AE04 INSULIN GLARGINE
Atc Name
a 10 ae 04
Aig Number
0147062001
Company Name
eli lilly canada inc
Company Address
SUITE 900, Exchange Tower, 130 King Street West, Toronto, Ontario, Canada, M5X 1B1
Active Ingredients
INSULIN GLARGINE
100 UNIT / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
4844682514caf3ba
Type
Standard
Back to Health Canada Approvals